Are there any laboratory biomarkers or other tools that can distinguish immune-mediated rheumatic diseases from other disorders and from possible complications, such as infections?
What conditions have to be excluded in the diagnostic workup of immune-mediated rheumatic diseases?
What is the difference between diagnostic and classification criteria of rheumatic diseases? What should we be aware of when using classification criteria in clinical practice?
Which common and rare adverse effects of biologic therapy should we consider during follow-up?
What has changed in the classification criteria of idiopathic inflammatory myopathies? What subgroups of patients can be distinguished and what are the differences between them?
How can we classify immune-mediated rheumatic diseases? Why is it particularly important to diagnose and treat them early?
What clinical features and laboratory test results suggest idiopathic inflammatory myopathy?
The number of indications for the use of biologic drugs in rheumatic diseases is growing. Which classes of biologics are currently used?
Are biologic drugs used in the treatment of macrophage activation syndrome?
English
Polski
Español
українська